ArticleScientific reports2025
Severe and enduring prostate cancer burden attributable to smoking among old men amid global decline and socioeconomic disparities.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanistic insights and clinical implications of RNA-binding proteins in prostate cancer.Discover oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Prostate cancer (PC) is a significant global health concern, particularly among older men (OM), and smoking is a well-established modifiable risk factor contributing to its incidence and mortality. However, a comprehensive assessment of the global burden of PC attributable to smoking among OM, with specific analyses by age and Socio-demographic Index (SDI) regions, is still lacking. This study utilized data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 to systematically analyze the global burden of PC attributable to smoking among OM (aged 55 years and older) from 1990 to 2021. The analysis included trends in deaths and Disability-Adjusted Life Years (DALYs) across different age groups and SDI regions. The estimated annual percentage change (EAPC) and Joinpoint regression analysis were employed to assess temporal trends. From 1990 to 2021, the global burden of PC attributable to smoking among OM exhibited a significant decline, with the age-standardized death rate decreasing from 3.08 per 100,000 in 1990 to 1.80 per 100,000 in 2021 (EAPC: -2.02, 95% CI: -2.14 to -1.90). Similarly, the age-standardized DALY rate decreased from 65.28 per 100,000 in 1990 to 37.75 per 100,000 in 2021 (EAPC: -2.05, 95% CI: -2.16 to -1.94). However, disparities across SDI regions were evident. The high SDI region experienced the most substantial decline in burden. In contrast, the low-middle SDI region showed an increasing trend, highlighting enduring socioeconomic disparities. Notably, Despite the overall reduction in the global burden, the burden among the older age group, specifically 90-95 years old, remained the most severe in 2021. This study reveals a complex landscape of the global burden of PC attributable to smoking among OM, with an overall decline masking enduring socioeconomic disparities and a severe burden among the older age group. These findings underscore the need for targeted interventions and public health strategies to address these disparities. Future efforts should focus on implementing smoking cessation programs and improving healthcare access in vulnerable populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.